Regeneron’s Q2 growth was led by Dupixent, EYLEA HD and Libtayo

Transcript intelligence

What changed

Q2 analysis added evidence of continued product momentum, including Dupixent’s record sales and EYLEA HD moving ahead of the original EYLEA. The pipeline focus also advanced toward cemdisiran, long-acting IL-13, obesity and Factor XI milestones.

Guidance delta

Maintained; the supplied analysis does not identify a change to overall guidance.

Key takeaways

• Management described double-digit revenue and non-GAAP EPS growth, led by Dupixent, EYLEA HD and Libtayo.
• Dupixent reached $6 billion in global net sales, up 38% in constant currency, according to the supplied analysis.
• EYLEA HD surpassed the original EYLEA in sales and represented about 60% of U.S. retina franchise revenue.
• Upcoming milestones include the FDA decision on cemdisiran, EYLEA HD prefilled-syringe review and Phase III obesity programs.
• Management highlighted a $15.1 billion cash position and continued R&D, repurchases and selective M&A capacity.

Management priorities

• Expand Dupixent through new age groups, indications and markets.
• Build EYLEA HD adoption through label expansion and dosing flexibility.
• Advance cemdisiran, long-acting IL-13, obesity and Factor XI programs.
• Continue oncology and rare-disease development.
• Maintain disciplined capital allocation and evaluate selective M&A.